Warsaw listed Ryvu Therapeutics, a clinical-stage drug discovery and development company has appointed Vatnak Vat-Ho as Chief Business Officer. Ryvu focuses on small molecule therapies that address emerging targets in oncology.
Vat-Ho will be responsible for strategic positioning, partnering discussions, alliance management as well as investor interactions. He brings almost 20 years of professional experience spanning pharma, biotech, as well as capital markets. For the first 10 years of his career, Vat-Ho worked in a variety of investment banks and global equity healthcare funds. He later moved to the pharma and biotech industry where he spent eight years at Pfizer. Most recently Vat-Ho served as VP, Business Development at Affimed, where he was responsible for leading partnering activities.
“We are very glad to welcome Vatnak to Ryvu as our first US-based colleague,” said Pawel Przewiezlikowski, CEO at Ryvu Therapeutics. “
“It’s an exciting opportunity to propel an already productive platform to bring important therapeutics to patients,” said Vat-Ho.